figure illustrates the percentage of patients who attained biochemical
remission (serum alkaline phosphatase activity within the normal range)
after receiving either 2 months of risedronate (30 mg/day) or 6 months
of etidronate (400 mg/day). At the 6-month observation, 77% of risedronate-treated
patients were in remission compared to 10% of etidronate-treated patients.
In the follow-up period, extending 16 months after risedronate treatment
was discontinued, 53% of patients were still in biochemical remission.
Overall, 90% of the risedronate patients had not relapsed.